In surprise flop, Regeneron, Sanofi report Dupixent PhIII failure, triggering premature trial stop
Dupixent, the seemingly infallible anti-inflammatory drug jointly developed by Regeneron and Sanofi, has flopped in a Phase III study.
Given to patients with chronic spontaneous urticaria — a condition characterized by the constant presence of hives — Dupixent failed to reach statistical significance on the primary endpoints of reducing itch and hives at an interim analysis.
Regeneron and Sanofi said the trial will be stopped due to futility.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.